LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

21.71 0.23

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.78

Максимум

22.1

Ключови измерители
By Trading Economics
Приходи	-10M -113M
Продажби	1.2M 9.7M
EPS	-1.1
Марж на печалбата	-1,162.384
Служители	510
EBITDA	-24M -121M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+97% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-256M 2.2B
Предишно отваряне	21.48
Предишно затваряне	21.71

Настроения в новините

By Acuity

58%

42%

319 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.11.2025 г., 17:45 ч. UTC

Печалби

Значими двигатели на пазара

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14.11.2025 г., 17:31 ч. UTC

Печалби

Значими двигатели на пазара

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14.11.2025 г., 16:15 ч. UTC

Значими двигатели на пазара

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14.11.2025 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14.11.2025 г., 23:02 ч. UTC

Пазарно говорене

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14.11.2025 г., 22:35 ч. UTC

Печалби

Придобивния, сливания и поглъщания

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14.11.2025 г., 22:32 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14.11.2025 г., 22:29 ч. UTC

Печалби

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14.11.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

14.11.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14.11.2025 г., 20:27 ч. UTC

Пазарно говорене

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14.11.2025 г., 20:23 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14.11.2025 г., 20:17 ч. UTC

Придобивния, сливания и поглъщания

Several State Attorneys General Oppose Railroad Merger -- WSJ

14.11.2025 г., 19:29 ч. UTC

Пазарно говорене

Печалби

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14.11.2025 г., 18:44 ч. UTC

Пазарно говорене

Печалби

Disney's Growth Now Hinges More on ESPN -- Market Talk

14.11.2025 г., 18:27 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.11.2025 г., 18:27 ч. UTC

Пазарно говорене

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14.11.2025 г., 18:20 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

14.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

14.11.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

14.11.2025 г., 16:51 ч. UTC

Пазарно говорене

Starbucks Gets Holiday Sales Lift -- Market Talk

14.11.2025 г., 16:48 ч. UTC

Пазарно говорене

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14.11.2025 г., 16:38 ч. UTC

Пазарно говорене

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14.11.2025 г., 16:30 ч. UTC

Придобивния, сливания и поглъщания

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14.11.2025 г., 16:28 ч. UTC

Пазарно говорене

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14.11.2025 г., 15:59 ч. UTC

Пазарно говорене

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14.11.2025 г., 15:06 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.11.2025 г., 15:06 ч. UTC

Пазарно говорене

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

97% нагоре

12-месечна прогноза

Среден 42.67 USD 97%

Висок 80 USD

Нисък 21 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

319 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.